Skip to main content

Merck’s COVID antiviral may be linked to virus mutations, study finds

Molnupiravir, which was granted an emergency use authorization by the FDA in December 2021, may allow mutated viruses to spread, a study has found.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.